BCAB - CIK 0001826892
The table below shows BioAtla, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.27M | -$16.29M | -$30.83M | -$22.65M | -$25.14M | -$14.99M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | $0.00 | $0.00 | -$50.00K | -$10.00K | -$501.00K |
| Dividends paid | - | - | - | - | - |
BioAtla, Inc. reported operating cash flow of -$48.20M for fiscal year 2025. That is up 33.0% from -$71.94M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.64M (FY 2019) to -$48.20M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $110.00K | -$395.00K | -$13.00K | -$116.00K | -$405.00K | -$1.91M |